Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6103)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 7, 2022 (publication date) through Apr 30, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Silva-Veiga FM, Miranda CS, Vasques-Monteiro IML, Souza-Tavares H, Martins FF, Daleprane JB, Souza-Mello V. Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice . World J Gastroenterol 2022; 28(17): 1814-1829 [PMID: 35633911 DOI: 10.3748/wjg.v28.i17.1814] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i17/1814.htm |
| Number | Citing Articles |
| 1 |
Qiuyu Xu, Jie Zhang, Yan Lu, Ling Wu. Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome. iScience 2024; 27(2): 108783 doi: 10.1016/j.isci.2024.108783
|
| 2 |
Tamiris Ingrid Petito‐da‐Silva, Felipe Missiba Villardi, Aline Penna‐de‐Carvalho, Carlos Alberto Mandarim‐de‐Lacerda, Vanessa Souza‐Mello, Sandra Barbosa‐da‐Silva. An Intestinal FXR Agonist Mitigates Dysbiosis, Intestinal Tight Junctions, and Inflammation in High‐Fat Diet‐Fed Mice. Molecular Nutrition & Food Research 2024; 68(4) doi: 10.1002/mnfr.202300148
|
| 3 |
Maja Grabacka, Przemysław M. Płonka, Małgorzata Pierzchalska. The PPARα Regulation of the Gut Physiology in Regard to Interaction with Microbiota, Intestinal Immunity, Metabolism, and Permeability. International Journal of Molecular Sciences 2022; 23(22): 14156 doi: 10.3390/ijms232214156
|
| 4 |
Ming Yang, Shuai Liu, Chunye Zhang. The Related Metabolic Diseases and Treatments of Obesity. Healthcare 2022; 10(9): 1616 doi: 10.3390/healthcare10091616
|
| 5 |
Isabela Macedo Lopes Vasques-Monteiro, Aline Fernandes-da-Silva, Carolline Santos Miranda, Flavia Maria Silva-Veiga, Julio Beltrame Daleprane, Vanessa Souza-Mello. Anti-steatotic effects of PPAR-alpha and gamma involve gut-liver axis modulation in high-fat diet-fed mice. Molecular and Cellular Endocrinology 2024; 585: 112177 doi: 10.1016/j.mce.2024.112177
|
| 6 |
Carolline Santos Miranda, Daiana Araujo Santana-Oliveira, Isabela Lopes Vasques-Monteiro, Nathan Soares Dantas-Miranda, Jade Sancha de Oliveira Glauser, Flavia Maria Silva-Veiga, Vanessa Souza-Mello. Time-dependent impact of a high-fat diet on the intestinal barrier of male mice. World Journal of Methodology 2024; 14(1): 89723 doi: 10.5662/wjm.v14.i1.89723
|
| 7 |
Henrique Souza-Tavares, Carolline Santos Miranda, Isabela Macedo Lopes Vasques-Monteiro, Cristian Sandoval, Daiana Araujo Santana-Oliveira, Flavia Maria Silva-Veiga, Aline Fernandes-da-Silva, Vanessa Souza-Mello. Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas. World Journal of Gastroenterology 2023; 29(26): 4136-4155 doi: 10.3748/wjg.v29.i26.4136
Abstract(315) |
Core Tip(298) |
Full Article(HTML)(1731)
|
Full Article with Cover (PDF)-2727K(91)
|
Full Article (Word)-1960K(27)
|
Audio-581K(4)
|
Peer-Review Report-312K(28)
|
Answering Reviewers-111K(28)
|
Full Article (PDF)-2462K(182)
|
Full Article (XML)-372K(27)
|
Times Cited (5)
|
Total Visits (3951)
|
Open
|
| 8 |
Yuan Zeng, Yifan Wu, Qian Zhang, Xinhua Xiao, Marcio Rodrigues. Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases. mBio 2024; 15(1) doi: 10.1128/mbio.02032-23
|
| 9 |
Haoran Jiang, Linquan Zang. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD. Current Pharmaceutical Design 2024; 30(2): 100 doi: 10.2174/0113816128283153231226103218
|